IXICO (LSE:IXI) Insider Ownership : 9.31 % (As of Jun. 08, 2024)

View and export this data going back to 1996. Start your Free Trial

What is IXICO Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, IXICO's insider ownership is 9.31%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, IXICO's Institutional Ownership is 6.67%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, IXICO's Float Percentage Of Total Shares Outstanding is 0.00%.

IXICO Insider Ownership Historical Data

The historical data trend for IXICO's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Insider Ownership Chart

IXICO Historical Data

The historical data trend for IXICO can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Insider Ownership	9.31	9.31	9.31	9.31	9.31	9.31	9.31	9.31	9.31	9.31

IXICO Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines